HIV and Hepatitis co-infection is common and contribute significantly to morbidity and mortality in persons living with HIV (PLWH). The objective of this study was to determine the prevalence of this co-infection in patients receiving second-line antiretroviral therapy in Pointe-Noire and Brazzaville.
Human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV) infections are common worldwide and are a major public health problem. The similarity of their transmission pathways (unprotected sex, blood transfusion, injecting drug use, mother-to-child transmission) probably explains the high frequency of co-infections of these viruses.
Out of a total of 261 HIV-positive patients, women accounted for more than half (55.17%), and slightly more than half (54.88%) were older than 40 years. Regarding co-infection, 4.21% (11/261) were co-infected with HIV/HBV, 6.89% (18/261) were co-infected with HIV/HCV and 0.38% (1/261) carried all three viruses. The overall prevalence of patients co-infected with hepatitis and HIV was 11.49%. Conversely, CD4+ cells are low, and less than 350 cells/μl stained CD4+ positive in all groups.
Although the rate of HIV and hepatitis co-infection seem to be low compare with what is known in sub-Saharan Africa, our results highlight the importance of screening PLWH for hepatitis in developing countries, especially in Congo.